Loading…
Performance of GenoType® MTBDRplus assay in the diagnosis of drug-resistant tuberculosis in Tangier, Morocco
•GenoType® MTBDRplus was introduced in Morocco to detect mutations conferring TB drug resistance.•In Tangier, among all suspected drug-resistant TB (DR-TB) cases, 37.1% were confirmed as multidrug-resistant (MDR).•rpoB531 and katG315 mutations were the most common mutations associated with RIF and I...
Saved in:
Published in: | Journal of global antimicrobial resistance. 2018-03, Vol.12, p.63-67 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •GenoType® MTBDRplus was introduced in Morocco to detect mutations conferring TB drug resistance.•In Tangier, among all suspected drug-resistant TB (DR-TB) cases, 37.1% were confirmed as multidrug-resistant (MDR).•rpoB531 and katG315 mutations were the most common mutations associated with RIF and INH resistance, respectively.•Sensitivity of GenoType® MTBDRplus was 92.1% for RIF and 97.4% for INH resistance; specificity was 100% for both.•GenoType® MTBDRplus is a rapid, reliable and accurate tool for detection of DR-TB in clinical specimens.
In Morocco, tuberculosis (TB) is a major public health problem with high morbidity and mortality. The main problem faced by the national TB programme is the high rate of drug-resistant (DR), particularly multi-drug resistant (MDR) strains. Diagnosis of DR-TB is mainly performed by conventional techniques that are time consuming with limited efficacy. In 2014, the GenoType® MTBDRplus assay was introduced in Morocco for drug susceptibility testing (DST). In this regard, the present study was planned to assess the diagnostic accuracy of the GenoType® MTBDRplus assay.
A total of 70 samples from suspected TB cases in Tangier (Morocco) were analysed by conventional DST and GenoType® MTBDRplus assay.
Among the 70 samples, 37.1% were MDR, whereas monoresistance to isoniazid (INH) and rifampicin (RIF) was detected in 186% and 17.1% of strains, respectively, by DST. Using the GenoType® MTBDRplus approach, 12 isolates (17.1%) were identified as INH monoresistant, 9 (12.9%) as RIF monoresistant and 26 (37.1%) as MDR. rpoB531 and katG315 mutations were the most common mutations associated with resistance to RIF and INH, respectively. Significantly, all phenotypically MDR strains were also MDR by GenoType® MTBDRplus. The sensitivity of GenoType® MTBDRplus was 92.1% for RIF resistance and 97.4% for INH resistance, whereas the specificity was 100% for the two tested drugs.
GenoType® MTBDRplus assay is a rapid, reliable and accurate tool for the detection of DR-TB in clinical specimens. Its routine use will be of a great interest to prevent the dissemination of DR-TB in the community. |
---|---|
ISSN: | 2213-7165 2213-7173 |
DOI: | 10.1016/j.jgar.2017.09.002 |